InvestorsHub Logo
Followers 0
Posts 3727
Boards Moderated 0
Alias Born 10/23/2017

Re: None

Wednesday, 05/12/2021 2:02:03 PM

Wednesday, May 12, 2021 2:02:03 PM

Post# of 704237
From the PR:

"The process outlined in the Company’s October 5, 2020 announcement relating to the Phase III trial of DCVax-L is continuing to move forward. The process includes review and analysis of the raw data by independent statisticians and experts, and preparation of summaries of the Trial results for review by the Company, the Principal Investigator, the Steering Committee of the Trial, the Scientific Advisory Board, and a panel of independent brain cancer experts in preparation for public announcement and scientific publication."

They then state:

"The Company continues to be in a quiet period while this process is under way. The Company appreciates shareholders’ patience, and their understanding that the Company cannot make partial disclosures during this process and cannot comment on the Phase III trial schedule or its data until the announcement of the results. We remain committed to completing the full plan outlined on October 5, 2020."

I detest the way they write their PR's. There was no "full plan" outlined in the October PR. Topline and Journal. that was the plan.
As far as the quiet period (self-imposed), there are only TWO processes in the plan.
1. Prepare the summaries of trial results and deliver to NWBO..."unblinding." This had to have happened by end of 2020 at latest, IMO.

2. Concurrent review by the "Company, the Principal Investigator, the Steering Committee of the Trial, the Scientific Advisory Board, and a panel of independent brain cancer experts." How long could that possibly take?

3. Is topline and Journal

Why can't they say where we are in the process? Ridiculous, IMO.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News